News

Here's some of what is coming soon to NeurologyLive® this week.

Lixisenatide, commonly used to treat type 2 diabetes, has the ability to cross the blood brain barrier and has shown neuroprotective properties in preclinical models of PD.

Significant thinning of GCIPL and INL appeared earlier in individuals with Parkinson disease, being discernible several years prior to clinical presentation.

The director of pharmacy at Emory Healthcare and Winship Cancer Institute talked about the role of pharmacists in multiple sclerosis patient care and collaborating with providers as biosimilars become available. [WATCH TIME: 5 minutes]

With limited options available in perimenstrual catamenial epilepsy, a phase 4 study seeks to understand whether an FDA-approved agent for focal onset seizures can effectively treat women with difficult-to-manage disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted and adjusted analysis.

Cervical dystonia, the most common form of focal dystonia, has shown to be able to be effectively managed with a variety of botulinum toxin formulations.

Neurology News Network for the week ending August 26, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 25, 2023.

The neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed strategies in managing the phases of multiple sclerosis for patients and the need for collaborative referral practices. [WATCH TIME: 5 minutes]

Despite a promising increase in the number of patients who receive preventive medications for migraine, a wide gap remains to effectively meet patient needs and reduce the burden of migraine.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicole Fowler. [LISTEN TIME: 23 minutes]

The injection therapy, branded as Tyruko, is indicated for the treatment of adults with MS, as well as those with severely active Crohn disease with inadequate response or tolerability to conventional therapy.

TSHA-102, an adeno-associated virus vector-based gene therapy for Rett Syndrome, has also received Orphan Drug and Rare Pediatric Disease designations from the FDA.

Autologous hematopoietic stem cell transplant was associated with a higher rate of recovery from disability than fingolimod and natalizumab, especially during the initial year posttreatment.

The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 3 minutes]

According to a recent study, malnutrition is related closely to quality of life among patients with NMOSD, caused by a variety of physiological and psychological factors.

Over a 3-treatment cycle, no new clinically significant safety observations were found, with significant dose-dependent increases in frataxin in muscle mRNA expression.

The executive vice president of the National MS Society provided perspective on the challenges with remyelinating strategies for patients with MS, and the progress that’s been made thus far. [WATCH TIME: 4 minutes]

Five-year data revealed sustained and significant improvement for patients with tremor as well as an overall improvement in quality of life measures and without any progressive or delayed complications.

The assistant professor at Hunter College talked about the importance of prioritizing accurate localization, appropriate diagnostic tests, and patient communication for effective neurological diagnosis, prognosis, and treatment. [WATCH TIME: 3 minutes]

The associate staff member in the department of neurology at Cleveland Clinic provided perspective on a recently published phase 1 study assessing deep brain stimulation in individuals with chronic poststroke hemiparesis.

Among a cohort of more than 70 individuals with MS, only 1 relapse occurred while on eculizumab, with significant reductions in immunosuppressive use observed.

The director of the Buffalo Neuroimaging Analysis Center talked about a study that explored cognitive decline in patients with early multiple sclerosis, underlining the significance of addressing cognitive impairment in the early stages of the disease. [WATCH TIME: 3 minutes]

In a clinical study diagnosing genetic disorders, genomic sequencing did not report 19 variants found by a targeted neonatal gene-sequencing test and the targeted panel did not report 164 variants recognized by genomic sequencing.

The associate staff member in the department of neurology at Cleveland Clinic provided background on a recently published phase 1 trial showing benefits of DBS for chonic poststroke motor rehabilitation. [WATCH TIME: 3 minutes]

Over a 28-day period, no adverse events led to study drug withdrawal, with decreased appetite as the most common treatment-related AE observed in the highest dosed cohort.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Erin Furr-Stimming, MD, FAAN, FANA. [LISTEN TIME: 11 minutes]

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly talked about the "Think Talk Treat Migraine" program and the 3 vital actions for providers take to improve migraine care for their patients. [WATCH TIME: 3 minutes]